Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Structure
2014 Feb 04;222:337-44. doi: 10.1016/j.str.2013.12.004.
Show Gene links
Show Anatomy links
Structure of the human FANCL RING-Ube2T complex reveals determinants of cognate E3-E2 selection.
Hodson C
,
Purkiss A
,
Miles JA
,
Walden H
.
???displayArticle.abstract???
The combination of an E2 ubiquitin-conjugating enzyme with an E3 ubiquitin-ligase is essential for ubiquitin modification of a substrate. Moreover, the pairing dictates both the substrate choice and the modification type. The molecular details of generic E3-E2 interactions are well established. Nevertheless, the determinants of selective, specific E3-E2 recognition are not understood. There are ∼40 E2s and ∼600 E3s giving rise to a possible ∼24,000 E3-E2 pairs. Using the Fanconi Anemia pathway exclusive E3-E2 pair, FANCL-Ube2T, we report the atomic structure of the FANCL RING-Ube2T complex, revealing a specific and extensive network of additional electrostatic and hydrophobic interactions. Furthermore, we show that these specific interactions are required for selection of Ube2T over other E2s by FANCL.
Figure 1. Overall Structure of FANCL-Ube2T Complex(A) The overall structure of the RING domain of FANCL (magenta) bound to Ube2T (blue) is shown in cartoon representation. Gray spheres represent zinc ions. A gold star represents the position of Ube2Tâs catalytic cysteine.(B) RING domain of FANCL (magenta) overlain with c-cbl RING domain (green; PDB ID code 1FBV).(C) Ube2T (blue) overlain with Ube2L3 (orange; PDB ID code 1FBV) showing the structural conservation of the UBC fold, comprising a four-stranded β-meander flanked by an N-terminal helix (helix1) and two C-terminal helices (helixes 2 and 3). A gold star represents the position of the catalytic cysteine. The gray oval shows the E3 binding interface of E2s.(D) Top left panel: The pi stacking in the binding interface between Y311 of FANCL and R6 and R9 of Ube2T. Top right panel: The hydrophobic binding interface of the RING domain (magenta) and Ube2T (blue). Bottom panels: The electrostatic and hydrogen bonding network of the RING-Ube2T interface. Interactions are represented by dashed lines.See also Figure S1.
Figure 2. Structural Comparison of the FANCL RING Domain-Ube2t Complex with Other RING-E2 Complexes(A) A structure-based sequence alignment of E2s. PDB ID codes of E2s, as listed in the figure: 1FBV, 3RPG, 4AP4, 4AUQ, 3RZ3, 2YB6, 3K9O, 3H8K, 2Z5D, 2F4W, 3HCT, and 3BZH.(B) A structure-based sequence alignment of RING and Ubox domains. Ubox domains are highlighted by a cyan box. PDB ID codes used of RING and Ubox domains, as listed in the figure: 1FBV, 4F52, 4AUQ, 3HCT, 2C2V, 3LIZ, 3RPG, 4AP4, 4EPO, 2YHO, 2Y43, 4KBL, and 4K7D. Residues shaded in red to yellow colors indicate conserved residues, where red corresponds to strict conservation. Gray bars indicate zinc coordinating atoms. Green circles highlight residues involved in the hydrophobic interface between FANCL and Ube2T. Purple circles denote residues involved in hydrogen bonding and electrostatic interactions in the FANCL Ube2T interface.(C) Superpositions of the FANCL RING-Ube2T complex (colored pink and blue, respectively), with c-cbl RING-Ube2L3 complex (left) shaded gray (PDB ID code 1FBV), idol-Ube2D1 complex (middle) shaded gray (PDB ID code 2YHO), and ring1b-Ube2D3 complex (right) shaded gray (PDB ID code 3RPG). Numbered residues are the same as the FANCL RING-Ube2T complex, with dashed lines showing interactions.
Figure 3. Conserved Hydrophobic RING Residues Are Required for Ube2T Binding and FANCL Selects Solely Ube2T In Vitro(A) Size-exclusion chromatogram profiles of wild-type (WT) or mutant RING domains (green dashed line) and WT Ube2T (blue dotted line) overlaid with profiles from binding experiments in which WT Ube2T has been incubated with WT or mutant RING domains (pink line) and subjected to size-exclusion chromatography. Binding was assessed by complex formation, which is indicated by a peak shift to the left labeled complex.(B) Size-exclusion chromatogram of FANCL RING domain incubated with an E2 mix consisting of Ube2T, Ube2D3, and Ube2L3 (pink line). Chromatograms of Ube2T (blue dotted line) and the RING domain (green dashed line) are also overlaid. A peak shift to the left is observed, indicating complex formation. SDS-PAGE gel of the fractions collected from the size-exclusion experiment and stained with Coomassie Brilliant Blue. The E2 gel bands found in the shifted peak were assessed by mass spectrometry for protein identification and confirmed as exclusively Ube2T.See also Figure S2.
Figure 4. Additional Residues of Ube2T Are Required for Binding the RING Domain of FANCL(A) Size-exclusion chromatogram profiles of wild-type (WT) or mutant Ube2T (blue) dotted line and WT RING domains (green dashed line) overlain with profiles from binding experiments in which WT RING domain has been incubated with WT or mutant Ube2T (pink line) and subjected to size-exclusion chromatography. Binding was assessed by complex formation indicated by a peak shift to the left.(B) An anti-HA-Ub western blot of in vitro monoubiquitination assays to assess monoubiquitination of FLAG-FANCD2 by FANCL in collaboration with different WT Ube2T and Ube2T mutants (Ube2TArg99Ser/Ser101Arg, Ube2TSer5Arg, and Ube2TArg60Glu). Lanes 2, 4, and 6 show the monoubiquitination of FLAG-FANCD2 when WT Ube2T, Ube2T Arg99Ser/Ser101Arg, and Ube2TSer5Arg are paired with FANCL. Monoubiquitination is not observed for with the Ube2TArg60Glu mutant is used (lane 8).
Afonine,
A robust bulk-solvent correction and anisotropic scaling procedure.
2005, Pubmed
Afonine,
A robust bulk-solvent correction and anisotropic scaling procedure.
2005,
Pubmed
Alpi,
Mechanistic insight into site-restricted monoubiquitination of FANCD2 by Ube2t, FANCL, and FANCI.
2008,
Pubmed
Alter,
Fanconi's anemia and malignancies.
1996,
Pubmed
Bailly,
Specific complex formation between yeast RAD6 and RAD18 proteins: a potential mechanism for targeting RAD6 ubiquitin-conjugating activity to DNA damage sites.
1994,
Pubmed
Bentley,
Recognition of UbcH5c and the nucleosome by the Bmi1/Ring1b ubiquitin ligase complex.
2011,
Pubmed
Brzovic,
Ubiquitin transfer from the E2 perspective: why is UbcH5 so promiscuous?
2006,
Pubmed
Chen,
The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site.
2006,
Pubmed
Cole,
The structure of the catalytic subunit FANCL of the Fanconi anemia core complex.
2010,
Pubmed
Davis,
MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes.
2004,
Pubmed
Deshaies,
RING domain E3 ubiquitin ligases.
2009,
Pubmed
Dou,
BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer.
2012,
Pubmed
Emsley,
Coot: model-building tools for molecular graphics.
2004,
Pubmed
Garcia-Higuera,
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
2001,
Pubmed
Hodson,
Structural analysis of human FANCL, the E3 ligase in the Fanconi anemia pathway.
2011,
Pubmed
Huang,
Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade.
1999,
Pubmed
Kar,
Human proteome-scale structural modeling of E2-E3 interactions exploiting interface motifs.
2012,
Pubmed
Knipscheer,
The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair.
2009,
Pubmed
,
Xenbase
Kottemann,
Fanconi anaemia and the repair of Watson and Crick DNA crosslinks.
2013,
Pubmed
Machida,
UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation.
2006,
Pubmed
Markson,
Analysis of the human E2 ubiquitin conjugating enzyme protein interaction network.
2009,
Pubmed
McCoy,
Phaser crystallographic software.
2007,
Pubmed
Meetei,
A novel ubiquitin ligase is deficient in Fanconi anemia.
2003,
Pubmed
Pellegrini,
Insights into DNA recombination from the structure of a RAD51-BRCA2 complex.
2002,
Pubmed
Pflugrath,
The finer things in X-ray diffraction data collection.
1999,
Pubmed
Pickart,
Ubiquitin: structures, functions, mechanisms.
2004,
Pubmed
Plechanovová,
Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis.
2012,
Pubmed
Pruneda,
Structure of an E3:E2~Ub complex reveals an allosteric mechanism shared among RING/U-box ligases.
2012,
Pubmed
Sato,
Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains.
2008,
Pubmed
Sheng,
A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase structure-function screen.
2012,
Pubmed
Starita,
Activity-enhancing mutations in an E3 ubiquitin ligase identified by high-throughput mutagenesis.
2013,
Pubmed
Timmers,
Positional cloning of a novel Fanconi anemia gene, FANCD2.
2001,
Pubmed
van den Ent,
RF cloning: a restriction-free method for inserting target genes into plasmids.
2006,
Pubmed
van Wijk,
The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins.
2010,
Pubmed
van Wijk,
A comprehensive framework of E2-RING E3 interactions of the human ubiquitin-proteasome system.
2009,
Pubmed
Wenzel,
UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids.
2011,
Pubmed
Winkler,
Structure-based approaches to create new E2-E3 enzyme pairs.
2005,
Pubmed
Ye,
Building ubiquitin chains: E2 enzymes at work.
2009,
Pubmed
Yin,
E2 interaction and dimerization in the crystal structure of TRAF6.
2009,
Pubmed
Zheng,
Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases.
2000,
Pubmed
